1932
0
  1. Home
  2. A-Z Publications
  3. Annual Review of Medicine
  4. Volume 71, 2020
  5. Article

Annual Review of Medicine

Volume 71, 2020

Bariatric Surgery as a Long-Term Treatment for Type 2 Diabetes/Metabolic Syndrome

Abstract

Metabolic surgery is increasingly becoming recognized as a more effective treatment for patients with type 2 diabetes (T2D) and obesity as compared to lifestyle modification and medical management alone. Both observational studies and clinical trials have shown metabolic surgery to result in sustained weight loss (20–30%), T2D remission rates ranging from 23% to 60%, and improvement in cardiovascular risk factors such as hypertension and dyslipidemia. Metabolic surgery is cost-effective and relatively safe, with perioperative risks and mortality comparable to low-risk procedures such as cholecystectomy, hysterectomy, and appendectomy. International diabetes and medical organizations have endorsed metabolic surgery as a standard treatment for T2D with obesity.

Keyword(s): bariatric surgery, cardiovascular risk factor, diabetes remission, metabolic surgery, type 2 diabetes, weight loss
Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-053117-123246
2020-01-27
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/med/71/1/annurev-med-053117-123246.html?itemId=/content/journals/10.1146/annurev-med-053117-123246&mimeType=html&fmt=ahah

Literature Cited

  1. 1. 
    Afshin A, Forouzanfar MH, Reitsma MB et al. 2017. Health effects of overweight and obesity in 195 countries over 25 years. N. Engl. J. Med. 377:113–27
     [Google Scholar]
  2. 2. 
    International Diabetes Federation 2017. IDF Diabetes Atlas. 8th ed. http://www.diabetesatlas.org/
  3. 3. 
    Bays HE, Chapman RH, Grandy S et al. 2007. The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys. Int. J. Clin. Pract. 61:737–47
     [Google Scholar]
  4. 4. 
    American Diabetes Association 2018. 7. Obesity management for the treatment of type 2 diabetes: Standards of Medical Care in Diabetes—2018. Diabetes Care 41:Suppl. 1S65–72
     [Google Scholar]
  5. 5. 
    American Diabetes Association 2018. 6. Glycemic targets: Standards of Medical Care in Diabetes—2018. Diabetes Care 41:Suppl. 1S55–64
     [Google Scholar]
  6. 6. 
    Pareek M, Schauer PR, Kaplan LM et al. 2018. Metabolic surgery: weight loss, diabetes, and beyond. J. Am. Coll. Cardiol. 71:6670–87
     [Google Scholar]
  7. 7. 
    Chatterjee S, Khunti K, Davies MJ 2017. Type 2 diabetes. Lancet 389:100852239–51
     [Google Scholar]
  8. 8. 
    Barnett AH. 2013. Complementing insulin therapy to achieve glycemic control. Adv. Ther. 30:557–76
     [Google Scholar]
  9. 9. 
    Davies MJ, Gagliardino JJ, Gray LJ et al. 2013. Real-world factors affecting adherence to insulin therapy in patients with type 1 or type 2 diabetes mellitus: a systematic review. Diabet. Med. 30:512–24
     [Google Scholar]
  10. 10. 
    Taylor R, Barnes AC. 2019. Can type 2 diabetes be reversed and how can this best be achieved? James Lind Alliance research priority number one. Diabet. Med. 36:3308–15
     [Google Scholar]
  11. 11. 
    Lean ME, Brosnahan N, Kean S et al. 2019. Two-year results of the randomised Diabetes Remission Clinical Trial (DiRECT). Lancet Diabetes Endocrinol 7:5344–55
     [Google Scholar]
  12. 12. 
    Gregg EW, Chen H, Wagenknecht LE et al. 2012. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA 308:232489–96
     [Google Scholar]
  13. 13. 
    Wing RR, Bolin P, Brancati FL et al. 2013. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N. Engl. J. Med. 369:145–54
     [Google Scholar]
  14. 14. 
    Kahn SE, Cooper ME, Del Prato S 2014. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 383:99221068–83
     [Google Scholar]
  15. 15. 
    Khunti K, Ceriello A, Cos X, De Block C 2018. Achievement of guideline targets for blood pressure, lipid, and glycaemic control in type 2 diabetes: a meta-analysis. Diabetes Res. Clin. Pract. 137:137–48
     [Google Scholar]
  16. 16. 
    Casagrande SS, Fradkin JE, Saydah SH et al. 2013. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988–2010. Diabetes Care 36:82271–79
     [Google Scholar]
  17. 17. 
    Cummings DE, Rubino F. 2018. Metabolic surgery for the treatment of type 2 diabetes in obese individuals. Diabetologia 61:2257–64
     [Google Scholar]
  18. 18. 
    Schauer PR, Mingrone G, Ikramuddin S, Wolfe B 2016. Clinical outcomes of metabolic surgery: efficacy of glycemic control, weight loss, and remission of diabetes. Diabetes Care 39:6902–11
     [Google Scholar]
  19. 19. 
    Rubino F, Nathan DM, Eckel RH et al. 2016. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care 39:6861–77
     [Google Scholar]
  20. 20. 
    English WJ, DeMaria EJ, Brethauer SA et al. 2018. American Society for Metabolic and Bariatric Surgery estimation of metabolic and bariatric procedures performed in the United States in 2016. Surg. Obes. Relat. Dis. 14:3259–63
     [Google Scholar]
  21. 21. 
    Flum DR, Belle SH, King WC et al. 2009. Perioperative safety in the longitudinal assessment of bariatric surgery. N. Engl. J. Med. 361:445–54
     [Google Scholar]
  22. 22. 
    Khan S, Rock K, Baskara A et al. 2016. Trends in bariatric surgery from 2008 to 2012. Am. J. Surg. 211:61041–46
     [Google Scholar]
  23. 23. 
    Chang SH, Stoll CR, Song J et al. 2014. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003–2012. JAMA Surg 149:3275–87
     [Google Scholar]
  24. 24. 
    Aminian A, Brethauer SA, Kirwan JP et al. 2015. How safe is metabolic/diabetes surgery?. Diabetes Obes. Metab. 17:198–201
     [Google Scholar]
  25. 25. 
    Maglione MA, Gibbons MM, Livhits M et al. 2013. Bariatric surgery and nonsurgical therapy in adults with metabolic conditions and a body mass index of 30.0 to 34.9 kg/m2 Comparative Effectiveness Reviews No. 82 Rockville, MD: US Agency for Healthcare Research and Quality https://www.ncbi.nlm.nih.gov/books/NBK148685/
  26. 26. 
    Sjöström L, Peltonen M, Jacobson P et al. 2014. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 311:2297–304
     [Google Scholar]
  27. 27. 
    Adams TD, Davidson LE, Litwin SE et al. 2017. Weight and metabolic outcomes 12 years after gastric bypass. N. Engl. J. Med. 377:121143–55
     [Google Scholar]
  28. 28. 
    Schauer PR, Bhatt DL, Kirwan JP et al. 2017. Bariatric surgery versus intensive medical therapy for diabetes—5-year outcomes. N. Engl. J. Med. 376:641–51
     [Google Scholar]
  29. 29. 
    Courcoulas AP, King WC, Belle SH et al. 2018. Seven-year weight trajectories and health outcomes in the Longitudinal Assessment of Bariatric Surgery (LABS) study. JAMA Surg 153:5427–34
     [Google Scholar]
  30. 30. 
    Sheng B, Truong K, Spitler H et al. 2017. The long-term effects of bariatric surgery on type 2 diabetes remission, microvascular and macrovascular complications, and mortality: a systematic review and meta-analysis. Obes. Surg. 27:102724–32
     [Google Scholar]
  31. 31. 
    Billeter AT, Scheurlen KM, Probst P et al. 2018. Meta‐analysis of metabolic surgery versus medical treatment for microvascular complications in patients with type 2 diabetes mellitus. Br. J. Surg. 105:3168–81
     [Google Scholar]
  32. 32. 
    Sjöström L, Peltonen M, Jacobson P et al. 2012. Bariatric surgery and long-term cardiovascular events. JAMA 307:56–65
     [Google Scholar]
  33. 33. 
    Buchwald H, Avidor Y, Braunwald E et al. 2004. Bariatric surgery: a systematic review and metaanalysis. JAMA 292:1724–37
     [Google Scholar]
  34. 34. 
    Maciejewski ML, Arterburn DE, Van Scoyoc L et al. 2016. Bariatric surgery and long-term durability of weight loss. JAMA Surg 151:1046–55
     [Google Scholar]
  35. 35. 
    Brethauer SA, Chand B, Schauer PR 2006. Risks and benefits of bariatric surgery: current evidence. Cleve. Clin. J. Med. 73:11993
     [Google Scholar]
  36. 36. 
    Salminen P, Helmiö M, Ovaska J et al. 2018. Effect of laparoscopic sleeve gastrectomy versus laparoscopic Roux-en-Y gastric bypass on weight loss at 5 years among patients with morbid obesity: the SLEEVEPASS randomized clinical trial. JAMA 319:3241–54
     [Google Scholar]
  37. 37. 
    Peterli R, Wölnerhanssen BK, Peters T et al. 2018. Effect of laparoscopic sleeve gastrectomy versus laparoscopic Roux-en-Y gastric bypass on weight loss in patients with morbid obesity: the SM-BOSS randomized clinical trial. JAMA 319:3255–65
     [Google Scholar]
  38. 38. 
    Buchwald H, Estok R, Fahrbach K et al. 2009. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am. J. Med. 122:248–56
     [Google Scholar]
  39. 39. 
    Madsen LR, Baggesen LM, Richelsen B, Thomsen RW 2019. Effect of Roux-en-Y gastric bypass surgery on diabetes remission and complications in individuals with type 2 diabetes: a Danish population-based matched cohort study. Diabetologia 62:4611–20
     [Google Scholar]
  40. 40. 
    Vest AR, Heneghan HM, Agarwal S et al. 2012. Bariatric surgery and cardiovascular outcomes: a systematic review. Heart 98:1763–77
     [Google Scholar]
  41. 41. 
    Vest AR, Heneghan HM, Schauer PR, Young JB 2013. Surgical management of obesity and the relationship to cardiovascular disease. Circulation 127:8945–59
     [Google Scholar]
  42. 42. 
    Arterburn DE, Olsen MK, Smith VA et al. 2015. Association between bariatric surgery and long-term survival. JAMA 313:62–70
     [Google Scholar]
  43. 43. 
    Reges O, Greenland P, Dicker D et al. 2018. Association of bariatric surgery using laparoscopic gastric banding, Roux-en-Y gastric bypass, or laparoscopic sleeve gastrectomy versus usual care obesity management with all-cause mortality. JAMA 319:3279–90
     [Google Scholar]
  44. 44. 
    Cardoso L, Rodrigues D, Gomes L, Carrilho F 2017. Short- and long-term mortality after bariatric surgery. Diabetes Obes. Metab. 19:91223–32
     [Google Scholar]
  45. 45. 
    Moussa OM, Erridge S, Chidambaram S et al. 2019. Mortality of the severely obese: a population study. Ann. Surg. 269:61087–91
     [Google Scholar]
  46. 46. 
    Aminian A, Zajichek A, Arterburn DE et al. 2019. Association of metabolic surgery with major adverse cardiovascular outcomes inpatients with type 2 diabetes and obesity. JAMA 322:1271–82
     [Google Scholar]
  47. 47. 
    Gloy VL, Briel M, Bhatt DL et al. 2013. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomized controlled trials. BMJ 347:f5934
     [Google Scholar]
  48. 48. 
    Dixon JB, O'Brien PE, Playfair J et al. 2008. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 299:316–23
     [Google Scholar]
  49. 49. 
    Schauer PR, Kashyap SR, Wolski K et al. 2012. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N. Engl. J. Med. 366:1567–76
     [Google Scholar]
  50. 50. 
    Schauer PR, Bhatt DL, Kirwan JP et al. 2014. Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. N. Engl. J. Med. 370:2002–13
     [Google Scholar]
  51. 51. 
    Mingrone G, Panunzi S, De Gaetano A et al. 2012. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N. Engl. J. Med. 366:1577–85
     [Google Scholar]
  52. 52. 
    Mingrone G, Panunzi S, De Gaetano A et al. 2015. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet 386:964–73
     [Google Scholar]
  53. 53. 
    Ikramuddin S, Korner J, Lee WJ et al. 2013. Roux-en-Y gastric bypass versus intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA 309:2240–49
     [Google Scholar]
  54. 54. 
    Ikramuddin S, Billington CJ, Lee WJ et al. 2015. Roux-en-Y gastric bypass for diabetes (the Diabetes Surgery Study): 2-year outcomes of a 5-year, randomized, controlled trial. Lancet Diabetes Endocrinol 3:413–22
     [Google Scholar]
  55. 55. 
    Ikramuddin S, Korner J, Lee WJ et al. 2018. Lifestyle intervention and medical management with versus without Roux-en-Y gastric bypass and control of hemoglobin A1c, LDL cholesterol, and systolic blood pressure at 5 years in the Diabetes Surgery Study. JAMA 319:3266–78
     [Google Scholar]
  56. 56. 
    Liang Z, Wu Q, Chen B et al. 2013. Effect of laparoscopic Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus with hypertension: a randomized controlled trial. Diabetes Res. Clin. Pract. 101:50–56
     [Google Scholar]
  57. 57. 
    Halperin F, Ding SA, Simonson DC et al. 2014. Roux-en-Y gastric bypass surgery or lifestyle with intensive medical management in patients with type 2 diabetes: feasibility and 1-year results of a randomized clinical trial. JAMA Surg 149:716–26
     [Google Scholar]
  58. 58. 
    Courcoulas AP, Goodpaster BH, Eagleton JK et al. 2014. Surgical versus medical treatments for type 2 diabetes mellitus: a randomized clinical trial. JAMA Surg 149:707–15
     [Google Scholar]
  59. 59. 
    Courcoulas AP, Belle SH, Neiberg RH et al. 2015. Three-year outcomes of bariatric surgery versus lifestyle intervention for type 2 diabetes mellitus treatment: a randomized clinical trial. JAMA Surg 150:931–40
     [Google Scholar]
  60. 60. 
    Wentworth JM, Playfair J, Laurie C et al. 2014. Multidisciplinary diabetes care with and without bariatric surgery in overweight people: a randomised controlled trial. Lancet Diabetes Endocrinol 2:545–52
     [Google Scholar]
  61. 61. 
    Parikh M, Chung M, Sheth S et al. 2014. Randomized pilot trial of bariatric surgery versus intensive medical weight management on diabetes remission in type 2 diabetic patients who do not meet NIH criteria for surgery and the role of soluble RAGE as a novel biomarker of success. Ann. Surg. 260:617–22
     [Google Scholar]
  62. 62. 
    Ding SA, Simonson DC, Wewalka M et al. 2015. Adjustable gastric band surgery or medical management in patients with type 2 diabetes: a randomized clinical trial. J. Clin. Endocrinol. Metab. 100:2546–56
     [Google Scholar]
  63. 63. 
    Cummings DE, Arterburn DE, Westbrook EO et al. 2016. Gastric bypass surgery versus intensive lifestyle and medical intervention for type 2 diabetes: the CROSSROADS randomized controlled trial. Diabetologia 59:945–53
     [Google Scholar]
  64. 64. 
    Shah SS, Todkar J, Phadake U et al. 2016. Gastric bypass versus medical/lifestyle care for type 2 diabetes in South Asians with BMI 25–40 kg/m2: the COSMID randomized trial [261-OR] Oral paper presented at the American Diabetes Association's 76th Scientific Session June 10–14 New Orleans, LA:
  65. 65. 
    Fouse T, Schauer P. 2016. The socioeconomic impact of morbid obesity and factors affecting access to obesity surgery. Surg. Clin. North Am. 96:669–79
     [Google Scholar]
  66. 66. 
    Rubin JK, Hinrichs-Krapels S, Hesketh R et al. 2016. Identifying barriers to appropriate use of metabolic/bariatric surgery for type 2 diabetes treatment: policy lab results. Diabetes Care 39:954–63
     [Google Scholar]
  67. 67. 
    Hoerger TJ, Zhang P, Segel JE et al. 2010. Cost-effectiveness of bariatric surgery for severely obese adults with diabetes. Diabetes Care 33:91933–39
     [Google Scholar]
  68. 68. 
    Consensus Development Conference Panel 1991. Gastrointestinal surgery for severe obesity. Ann. Intern. Med. 115:956–61
     [Google Scholar]
  69. 69. 
    American Diabetes Association 2019. Standards of medical care in diabetes—2019. Diabetes Care 42:Suppl. 1)
     [Google Scholar]
  70. 70. 
    Davies MJ, D'Alessio DA, Fradkin J et al. 2018. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 61:122461–98
     [Google Scholar]
  71. 71. 
    Ghio B, Jiménez A, Corcelles R et al. 2017. Midterm effects of bariatric surgery in patients with insulin-treated type 2 diabetes. Surg. Obes. Relat. Dis. 13:122004–9
     [Google Scholar]
  72. 72. 
    Rubino F, Nathan DM, Eckel RH et al. 2016. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care 39:861–77
     [Google Scholar]
  73. 73. 
    Aminian A, Brethauer SA, Andalib A et al. 2017. Individualized metabolic surgery score: procedure selection based on diabetes severity. Ann. Surg. 266:4650–57
     [Google Scholar]
  74. 74. 
    Still CD, Wood GC, Benotti P et al. 2014. Preoperative prediction of type 2 diabetes remission after Roux-en-Y gastric bypass surgery: a retrospective cohort study. Lancet Diabetes Endocrinol 2:138–45
     [Google Scholar]
  75. 75. 
    Lee WJ, Hur KY, Lakadawala M et al. 2013. Predicting success of metabolic surgery: age, body mass index, C-peptide, and duration score. Surg. Obes. Relat. Dis. 9:3379–84
     [Google Scholar]
  76. 76. 
    Lee WJ, Chong K, Chen SC et al. 2016. Preoperative prediction of type 2 diabetes remission after gastric bypass surgery: a comparison of DiaRem scores and ABCD scores. Obes. Surg. 26:102418–24
     [Google Scholar]
  77. 77. 
    Brethauer SA, Aminian A, Romero-Talamás H et al. 2013. Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann. Surg. 258:628–36
     [Google Scholar]
  78. 78. 
    Hanipah ZN, Schauer PR. 2017. Surgical treatment of obesity and diabetes. Gastrointest. Endosc. Clin. N. Am. 27:2191–211
     [Google Scholar]
  79. 79. 
    Schauer PR, Nor HZ, Rubino F 2017. Metabolic surgery for treating type 2 diabetes mellitus: now supported by the world's leading diabetes organizations. Cleve. Clin. J. Med. 84:7 Suppl. 1S47
     [Google Scholar]
/content/journals/10.1146/annurev-med-053117-123246
Loading
Bariatric Surgery as a Long-Term Treatment for Type 2 Diabetes/Metabolic Syndrome
Annual Review of Medicine 71, 1 (2020); https://doi.org/10.1146/annurev-med-053117-123246
/content/journals/10.1146/annurev-med-053117-123246
/content/journals/10.1146/annurev-med-053117-123246
Loading

Data & Media loading...

  • Article Type: Review Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error